Cureline Group’s Full Range of Research Services Now Available Through Scientist.com
25.7.2023 14:55:00 EEST | Business Wire | Press release
Cureline Group, an industry pioneer in precision and translational medicine, today announced its plans to showcase its full spectrum of research products and services on Scientist.com, the premier preclinical research marketplace for the biopharma sector. Biopharma researchers utilizing Scientist.com can now quickly and economically access essential services such as biobanking (including collection, processing, storage and retrieval of biological samples), human sample validation (including biomarker identification and verification), preclinical animal services and preclinical project management (protocol design, study execution and data analysis), histopathology, digital pathology and other lab services that are critical to accelerating drug discovery and development.
“We are excited to continue our longstanding partnership with Scientist.com, which has helped us connect with many biopharma researchers at top pharma and biotech companies,” stated Dr. Olga Potapova, Founder and CEO of the Cureline Group. “With our 20 years of translational CRO experience, we want to make it easy for any industry or academic scientist to access the many innovative tools and technologies and regulatory expertise that we’ve brought together under one roof.”
The Cureline Group, comprised of an array of companies including Cureline, Inc., Cureline BioPathology (CBP), Cureline Molecular Services (CMS), Cureline Baltic UAB, DolceRx Baltika UAB and the newly formed Memel Biotech, offers an extensive portfolio of ISO-certified, CAP-compliant preclinical research and biomarker/companion diagnostics services. Clinical expertise will be delivered by the recent strategic partnership of palleos healthcare (Germany) and Cureline. Offering clients a full-service approach can help reduce complexity and save time.
“The Cureline Group has evolved into a one-stop shop for high-quality research services in the preclinical research and biomarker/companion diagnostic spaces,” stated Kevin Lustig, PhD, Founder and CEO at Scientist.com. "We are delighted to feature their services on Scientist.com’s fast-growing, AI-powered marketplace."
About Cureline, Inc., and the Cureline Group of companies:
As a global leader in commercial biobanking and translational research services celebrating 20 years in business in 2023, we have completed over 5,000 projects for 850 clients. Cureline, Inc., (USA) together with other Cureline Group companies, is a global precision and translational medicine contract research organization (CRO) providing biobanking and HBS services in the preclinical phase and companion diagnostics development for clinical trials to the biopharmaceutical industry. Cureline Group management are experts in global regulatory affairs, custom protocol biobanking, histopathology & digital pathology, molecular and cellular lab services, small animal studies and cell and gene therapy (ATMP) solutions. Since 2021, UAB Cureline Baltic (Lithuania) is servicing our clients' needs in animal toxicology and preclinical efficacy studies in small animals with a focus on metastatic cancer, immunology and microbiota models. Starting in 2024, Memel Biotech UAB (Lithuania) will be providing GMP CDMO service for the ATMP clinical research community.
Visit http://www.cureline.com/ to learn more.
About Scientist.com
Scientist.com's mission is to empower and connect scientists worldwide. The company's AI-powered research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management. Scientist.com connects the world's top pharmaceutical companies, biotechnology companies and the US National Institutes of Health (NIH) to the world's largest network of scientific suppliers.
Visit Scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
About palleos healthcare GmbH
palleos healthcare is a full-service CRO with 50 highly experienced employees covering Phase I – IV drug and medical device clinical research services in central Europe. More than 10,000 patients at 300 sites were treated in various trials and indications with the results published in highly ranked journals. palleos healthcare also offers drug development consulting services for biotech and medtech companies, streamlining their early and pre-clinical development decisive milestones, allowing earlier and more efficient exit and reinvestment. As a certified partner with best-in-class players in the digital life science field (Veeva, Medidata, etc.), palleos healthcare offers cloud-based services for data management and decentralized clinical trials.
Visit www.palleos.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230725851885/en/
Contact information
Media Contact:
Olga Potapova, CEO, The Cureline Group
+1 415-468-6400 ext. 221
olga-potapova@cureline.com
Sean Preci, Sr. Director, Marketing & Content, Scientist.com
+1 858 771-3813 ext. 187
marketing@scientist.com
Heiko Bergmann, VP Sales & Strategy, palleos healthcare GmbH
+49 611 950 190 0 ext. 50
heiko.bergmann@palleos.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UAE Commits $49bn to Local Manufacturers7.5.2026 17:00:00 EEST | Press release
The United Arab Emirates (UAE) pledged $49 billion in industrial procurement opportunities on Monday and announced plans to localize more than 5,000 products as the Gulf state doubled down on its industrial sovereignty agenda. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507855698/en/ UAE commits $49bn to local manufacturers (Photo: AETOSWire) Dr. Sultan Al Jaber, UAE Minister of Industry and Advanced Technology, made the announcement at the opening of the fifth edition of Make it in the Emirates, which follows a period that has tested the region. “History remembers the challenges nations face. But it also remembers how nations respond to them and what they build next,” he said. TA’ZIZ announced $40.5 billion worth of agreements aimed at expanding UAE chemical production capacity. The opportunities include offtakes and $2 billion of financing for the UAE’s first world-scale methanol plant. A $270 million National Indust
Andersen Consulting Strengthens Organizational Transformation Capabilities with Afiniti7.5.2026 16:30:00 EEST | Press release
Andersen Consulting announces a Collaboration Agreement with Afiniti, a global business transformation consultancy headquartered in the United Kingdom that helps organizations deliver and sustain complex change programs. Founded in 2003, Afiniti is a global business change consultancy based in the UK and U.S., supporting clients through complex transformation across people, process, systems, and data, and bringing change to life through creative consulting services. The firm primarily serves highly regulated, safety-driven, and asset-intensive organizations with large, geographically dispersed workforces across sectors including energy, utilities, life sciences, transport, and construction. Afiniti works with well-known brands to deliver end-to-end expertise across organizational, digital and AI, cultural, and operating model transformation, particularly in complex scenarios such as mergers and acquisitions, large-scale technology adoption, and underperforming change programs that have
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom